PE20141296A1 - Composiciones y metodos para tratar el virus de la hepatitis c - Google Patents

Composiciones y metodos para tratar el virus de la hepatitis c

Info

Publication number
PE20141296A1
PE20141296A1 PE2014000749A PE2014000749A PE20141296A1 PE 20141296 A1 PE20141296 A1 PE 20141296A1 PE 2014000749 A PE2014000749 A PE 2014000749A PE 2014000749 A PE2014000749 A PE 2014000749A PE 20141296 A1 PE20141296 A1 PE 20141296A1
Authority
PE
Peru
Prior art keywords
virus
compositions
methods
magazine
refers
Prior art date
Application number
PE2014000749A
Other languages
English (en)
Spanish (es)
Inventor
Darryl G Cleary
Charles J Reynolds
Miriam Michelle Berrey
Robert G Hindes
William T Symonds
Adrian S Ray
Hongmei Mo
Christy M Hebner
Reza Oliyal
Vahid Zia
Dimitrios Stefanidis
Rowchanak Pakdaman
Melissa Jean Casteel
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56291296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of PE20141296A1 publication Critical patent/PE20141296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2014000749A 2011-11-29 2012-11-27 Composiciones y metodos para tratar el virus de la hepatitis c PE20141296A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus
PCT/US2012/066605 WO2013082003A1 (en) 2011-11-29 2012-11-27 Compositions and methods for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
PE20141296A1 true PE20141296A1 (es) 2014-10-08

Family

ID=56291296

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000749A PE20141296A1 (es) 2011-11-29 2012-11-27 Composiciones y metodos para tratar el virus de la hepatitis c

Country Status (21)

Country Link
EP (2) EP3777867A1 (OSRAM)
JP (2) JP5899327B2 (OSRAM)
KR (1) KR101560994B1 (OSRAM)
CN (1) CN104039319B (OSRAM)
AR (1) AR089578A1 (OSRAM)
AU (1) AU2012346217B2 (OSRAM)
BR (1) BR112014012739A8 (OSRAM)
CA (1) CA2856529C (OSRAM)
CO (1) CO6970603A2 (OSRAM)
EA (1) EA027296B1 (OSRAM)
EC (1) ECSP14005678A (OSRAM)
ES (1) ES2817886T3 (OSRAM)
MD (1) MD4430C1 (OSRAM)
MX (1) MX2014006373A (OSRAM)
PE (1) PE20141296A1 (OSRAM)
PH (1) PH12014501133B1 (OSRAM)
SG (1) SG11201402609RA (OSRAM)
TW (1) TWI566773B (OSRAM)
UY (1) UY34474A (OSRAM)
WO (1) WO2013082003A1 (OSRAM)
ZA (1) ZA201404061B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
US20170080008A1 (en) * 2014-03-05 2017-03-23 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
CA2988393C (en) * 2014-06-13 2023-08-22 Ratiopharm Gmbh Solid state forms of sofosbuvir
WO2015197535A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
US20170112867A1 (en) * 2014-06-23 2017-04-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of sofosbuvir and ribavirin
EA201692515A1 (ru) * 2014-06-23 2017-05-31 Сановель Илач Санайи Ве Тиджарет А.Ш. Новая фармацевтическая композиция на основе софосбувира и рибавирина
CN105267232A (zh) * 2014-06-30 2016-01-27 康普药业股份有限公司 一种用于治疗丙型肝炎的药物制剂及其制备方法
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
US20170296570A1 (en) * 2014-10-08 2017-10-19 Sandoz Ag High Drug Load Tablets Comprising Sofosbuvir
CN104546783A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种索非布韦薄膜包衣片制剂及其制备方法
CN104622836B (zh) * 2014-12-23 2020-02-21 浙江华海药业股份有限公司 索非布韦包衣片剂及其制备方法
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
WO2016156330A1 (en) * 2015-03-30 2016-10-06 Ratiopharm Gmbh Solid pharmaceutical composition comprising amorphous sofosbuvir and a phospholipid
CN104840964B (zh) * 2015-05-07 2018-01-16 南京正大天晴制药有限公司 一种稳定的索氟布韦药物组合物及其制备方法
CZ2015443A3 (cs) 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
CN104906062B (zh) * 2015-06-30 2018-05-25 浙江天顺生物科技有限公司 一种索非布韦的片剂及其制备方法
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CA3033858A1 (en) 2016-08-19 2018-02-22 Sandoz Ag Sofosbuvir derivatives for the treatment of hepatitis c
CZ2016553A3 (cs) 2016-09-09 2018-03-21 Zentiva, K.S. Pevná farmaceutická dávková forma obsahující sofosbuvir
CN106667936B (zh) * 2016-12-31 2021-02-05 江苏科本药业有限公司 一种索非布韦片剂及其制备方法
CN107041873B (zh) * 2017-02-17 2020-02-28 杭州青玥医药科技有限公司 索氟布韦包衣片剂的制备方法
CN106880642B (zh) * 2017-02-17 2019-08-06 杭州青玥医药科技有限公司 索氟布韦药物组合物及其制备方法
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN110604726B (zh) * 2019-07-19 2022-06-07 株洲千金药业股份有限公司 一种索非布韦组合物及其应用
CN111072742B (zh) * 2019-12-23 2022-12-02 南京正大天晴制药有限公司 一种治疗丙肝药物的新晶型及其组合物
CN111973566A (zh) * 2020-07-23 2020-11-24 石药集团中奇制药技术（石家庄）有限公司 一种索磷布韦片

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
JP2010519339A (ja) * 2007-02-26 2010-06-03 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｃｖ複製阻害剤として有用な三級アミン置換ペプチド
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
DK2061513T3 (da) 2007-09-14 2011-11-21 Schering Corp Fremgangsmåde til behandling af patienter med hepatitis C
DE102007052070A1 (de) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
DE102008057284A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
AU2009316472B2 (en) * 2008-11-20 2015-07-09 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus
DE102009015702A1 (de) * 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
US8618076B2 (en) * 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011009961A1 (en) * 2009-07-24 2011-01-27 Virologik Gmbh Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
SMT201700412T1 (it) * 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype

Also Published As

Publication number Publication date
KR101560994B1 (ko) 2015-10-15
EP3777867A1 (en) 2021-02-17
EP2785340B1 (en) 2020-07-15
AU2012346217B2 (en) 2016-02-04
WO2013082003A1 (en) 2013-06-06
ECSP14005678A (es) 2015-12-31
EA027296B1 (ru) 2017-07-31
JP2014533733A (ja) 2014-12-15
CN104039319A (zh) 2014-09-10
PH12014501133A1 (en) 2014-09-01
JP2016053096A (ja) 2016-04-14
AR089578A1 (es) 2014-09-03
TW201325599A (zh) 2013-07-01
BR112014012739A8 (pt) 2017-06-20
NZ625532A (en) 2016-07-29
ES2817886T3 (es) 2021-04-08
CO6970603A2 (es) 2014-06-13
CA2856529A1 (en) 2013-06-06
CN104039319B (zh) 2017-12-29
MD4430B1 (ro) 2016-08-31
TWI566773B (zh) 2017-01-21
MD4430C1 (ro) 2017-03-31
PH12014501133B1 (en) 2014-09-01
KR20140108645A (ko) 2014-09-12
MX2014006373A (es) 2014-07-22
AU2012346217A1 (en) 2014-06-19
BR112014012739A2 (pt) 2017-06-13
EA201490903A1 (ru) 2014-11-28
ZA201404061B (en) 2016-09-28
SG11201402609RA (en) 2014-06-27
JP5899327B2 (ja) 2016-04-06
CA2856529C (en) 2018-03-06
UY34474A (es) 2013-06-28
HK1202268A1 (en) 2015-09-25
EP2785340A1 (en) 2014-10-08
MD20140058A2 (en) 2014-11-30

Similar Documents

Publication Publication Date Title
PE20141296A1 (es) Composiciones y metodos para tratar el virus de la hepatitis c
BR112012017402A2 (pt) inibidores de vírus de flaviviridae
MX384836B (es) Agentes antivirales contra la hepatitis b
UA111841C2 (uk) Сполуки бензотіазолу та їх фармацевтичне застосування
TN2016000090A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors.
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201290576A1 (ru) Ингибиторы вирусов flaviviridae
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
NZ739248A (en) Inhibitors of hepatitis c virus
IN2012DN01855A (OSRAM)
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
MX2015008187A (es) Inhibidores de alk deuterados.
MX350746B (es) Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
WO2014152716A8 (en) Substituted heterocyclic compounds for treating or preventing viral infections
MX2015013240A (es) Método para proporcionar neuroprotección ocular.
EA201590006A1 (ru) Комбинация терапевтических средств для лечения инфекции, вызванной вирусом гепатита c
WO2013028615A3 (en) Novel cyclosporin derivatives for the treatment and prevention of viral infections
UY33939A (es) Inhibidores de la péptido desformilasa
EA019080B9 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА

Legal Events

Date Code Title Description
FG Grant, registration